42,500 Shares in Becton, Dickinson and Company $BDX Bought by Pacific Capital Partners Ltd

Key Points

• Pacific Capital Partners Ltd has acquired 42,500 shares of Becton, Dickinson and Company (BDX), valued at approximately $7.32 million, making it the second largest holding in their portfolio.
• Major investors like GQG Partners LLC and Vanguard Group have increased their stakes in BDX, indicating strong institutional interest, with 86.97% of the stock owned by such investors.
• Becton, Dickinson recently announced a quarterly dividend of $1.04 per share, representing an annual yield of 2.2% and a payout ratio of 74.82%.

Pacific Capital Partners Ltd acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,500 shares of the medical instruments supplier's stock, valued at approximately $7,321,000. Becton, Dickinson and Company makes up 6.9% of Pacific Capital Partners Ltd's investment portfolio, making the stock its 2nd largest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northcape Wealth Management LLC raised its stake in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after acquiring an additional 51 shares during the period. Alpha Omega Wealth Management LLC raised its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after acquiring an additional 53 shares during the period. Brady Family Wealth LLC raised its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after acquiring an additional 53 shares during the period. Diversified Trust Co raised its stake in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after acquiring an additional 53 shares during the period. Finally, REAP Financial Group LLC raised its stake in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock worth $551,536 over the last ninety days. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BDX shares. Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Piper Sandler reiterated a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday. Finally, Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $213.30.

Becton, Dickinson and Company Trading Down 0.9%

BDX traded down $1.63 during trading on Friday, hitting $186.74. The company's stock had a trading volume of 596,671 shares, compared to its average volume of 2,534,622. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock's fifty day moving average price is $187.42 and its 200-day moving average price is $190.65. The firm has a market capitalization of $53.52 billion, a P/E ratio of 33.56, a PEG ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the firm earned $3.50 earnings per share. The company's revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.